Dear Value Seeker,

Yesterday, the “Big Three” automakers came to Washington with a plan: ask for even more money.

GM wants $18 billion, with $4 billion for December’s bills.

Chrysler says it needs $7 billion in the next few months.

Ford is after $9 billion…but only as a precaution. It feels pretty confident it can make it without help.

After all, Ford’s sales fell only 31% year-over-year in November. GM and Chrysler both saw sales for the same period tumble by over 40%.

In exchange for $34 billion in taxpayer money, the automakers promised major restructuring, reduced labor costs (that’s right, it’s promising to fire employees in return for taxpayer backing) and the sale of some product lines.

The CEOs even said they would even work for $1. (Never mind that their salaries only make up about 10% of their overall pay packages.)

But decades of waste and mismanagement aren’t forgotten

Laura Cadden says Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is on the verge of a big breakthrough with a drug to treat sleep disorders. She says investors that buy the stock at or below 75 cents will be in line for double-digit gains.

This from Today’s Financial News:

Maryland-based Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) has high hopes for its drug VEC-162. This treatment mimics the action of melatonin — the hormone that that regulates the body’s internal clock.

Vanda is testing the effectiveness of VEC-162 to treat sleep disorders.

Over 60 million adults in the U.S. alone suffering from some form of insomnia. Yet only about 15% seek treatment. Some fear side effects like grogginess and dry mouth.

Others are afraid of becoming reliant on a sleep aid. In fact, many such treatments, including Lunesta and Ambien, are